NPM1 mutation was exclusively observed in KMT2Awt (17.5% vs. 0.2%; p < 0.0001), suggesting that in patients with KMT2Ar AML, the chances of identifying NPM1 are extremely low, at <0.5%. This evidence concerns the gene NPM1 and acute myeloid leukemia.